All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Interleukin-22 levels in pediatric patients with gastrointestinal graft-versus-host disease
Dana T. Lounder from Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA, and colleagues conducted a study to determine the role of circulating interleukin-22 (IL-22) levels in gastrointestinal graft-versus-host disease (GI GvHD) in pediatric patients undergoing hematopoietic stem cell transplant (HSCT). The study was published in Haematologica.
In order to assess whether IL-22 levels are elevated in pediatric patients with GI GvHD, the researchers analysed plasma samples obtained from 114 pediatric patients enrolled in a prospective cohort study, the Cincinnati Children’s Hospital Medical Center BMT repository. At 30-days post-transplant, IL-22, IL-22 binding protein (IL-22BP), Reg3α, and IL-17 levels were analyzed using ELISA.
Patient characteristics:
- Median age: 8 years (range, 0.4–32)
- GvHD any site: 50 (44%)
- Grade 1: 9 (18%)
- Grades 2–4: 41 (82%)
Key findings:
Data is given as GvHD patients with IL levels above the median vs GvHD patients with IL levels below the median
- IL-22
- The cumulative incidence of new onset acute GI GvHD 30 days after HSCT: 15.5% vs8%, P = 0.04
- 1-year treatment-related mortality (TRM) rate: 46.9% vs 20%, P = 0.6
- IL-22BP
- IL-22BP levels negatively correlated with IL-22 levels 30 days after HSCT, r = -0.2, P = 0.03
- There was no significant association between IL-22BP levels and the development of GI GvHD
- IL-17
- Incidence of GI GvHD 100 days after HSCT: 32% vs 14%, P = 0.03
- IL-17 levels significantly correlated with IL-22 levels 30 days after HSCT: r = 0.43, P < 0.0001
- Reg3α
- Reg3α levels negatively correlated with IL-22 levels: r = -0.22, P = 0.02
- Reg3α levels also negatively correlated with IL-17 levels: r = -0.47, P < 0.0001
Taken together, this data indicates that IL-22 levels are elevated in patients with GI graft-versus-host disease without causing higher mortality rates in this patient population. The research group stated that because of the complex role of IL-22 as well as related molecules in the setting of post-transplant patients, further studies are required to completely clarify the method of these mechanisms.
References